Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1067721
Abstract: Objective This study aimed to investigate the efficacy and safety of belimumab for treating children with refractory childhood-onset systemic lupus erythematosus (cSLE). Methods Twenty-six cSLE patients who received belimumab treatment in our hospital from January… read more here.
Keywords: safety; belimumab treatment; systemic lupus; lupus erythematosus ... See more keywords
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1074044
Abstract: Objective To obtain real-world data on outcomes of belimumab treatment and respective prognostic factors in patients with systemic lupus erythematosus (SLE). Methods Observational study of 188 active SLE patients (median disease duration 6.2 years, two… read more here.
Keywords: belimumab treatment; systemic lupus; observational study; lupus erythematosus ... See more keywords
The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1080730
Abstract: Objective: To examine the kinetics of B cell subsets and activation markers in the early stage of belimumab treatment and their correction with treatment response. Methods: We enrolled 27 systemic lupus erythematosus (SLE) patients receiving… read more here.
Keywords: cell; belimumab treatment; activation markers; systemic lupus ... See more keywords